Health Care

CEO Paul Gudonis’s 19,395‑RSU salary‑swap deal at Myomo signals insider confidence, aligns interests, and may calm volatility while boosting long‑term investor sentiment.

Insider buys at Bioventus signal strong confidence in its upcoming biotech milestones, offering investors a bullish view on future growth and IPO potential.

HeartFlow CEO Farquhar’s recent April sale shows a disciplined, schedule‑based exit amid a 38% YTD rally, underscoring management confidence and alignment with shareholders.

Liquidia insiders buy shares in a planned 10b‑5‑1 scheme, signalling confidence in its nanoparticle drug‑delivery platform ahead of key clinical milestones.

Veracyte insiders boost confidence with fresh share purchases amid a strong pipeline and rising stock, signaling leadership’s bullish outlook.

Ginkgo Bioworks CFO’s fresh share purchase signals strong insider confidence—insight into how insider buying aligns with cash‑flow targets and future growth prospects.

Insider selling in Veeva: Priscilla’s 750‑share sale amid a 27% drop shows liquidity moves, not a loss of confidence, and may signal a buying opportunity for value investors.

Sunshine Biopharma’s zero‑cost 100k‑share award from owner Natan David signals insider confidence amid a falling stock, raising hopes for future clinical wins.

Insider option activity at ImmuCell shows confidence in its rising biotech focus—free‑cost exercises suggest insiders see undervalued upside, potentially boosting future share performance.

Charlotte’s Web Holdings insider buying shows confidence amid price volatility, hinting at a breakout if the cannabinoid wellness firm sustains growth.